AU2020395907A1 - Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment - Google Patents

Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment Download PDF

Info

Publication number
AU2020395907A1
AU2020395907A1 AU2020395907A AU2020395907A AU2020395907A1 AU 2020395907 A1 AU2020395907 A1 AU 2020395907A1 AU 2020395907 A AU2020395907 A AU 2020395907A AU 2020395907 A AU2020395907 A AU 2020395907A AU 2020395907 A1 AU2020395907 A1 AU 2020395907A1
Authority
AU
Australia
Prior art keywords
agonist
dose
per
body weight
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020395907A
Other languages
English (en)
Inventor
Marc Peeters
Evelien Smits
Jonas VANAUDENAERDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Universiteit Antwerpen
Original Assignee
Ziekenhuis Antwerpen, University of
Universiteit Antwerpen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziekenhuis Antwerpen, University of, Universiteit Antwerpen filed Critical Ziekenhuis Antwerpen, University of
Publication of AU2020395907A1 publication Critical patent/AU2020395907A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020395907A 2019-12-06 2020-12-04 Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment Pending AU2020395907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214049.9 2019-12-06
EP19214049 2019-12-06
PCT/EP2020/084665 WO2021110930A1 (en) 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Publications (1)

Publication Number Publication Date
AU2020395907A1 true AU2020395907A1 (en) 2022-07-21

Family

ID=68808124

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020395907A Pending AU2020395907A1 (en) 2019-12-06 2020-12-04 Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment

Country Status (8)

Country Link
US (1) US20220411524A1 (https=)
EP (1) EP4069739A1 (https=)
JP (1) JP2023505303A (https=)
CN (1) CN115052891A (https=)
AU (1) AU2020395907A1 (https=)
CA (1) CA3163777A1 (https=)
IL (1) IL293613A (https=)
WO (1) WO2021110930A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523181A (ja) * 2021-06-03 2024-06-28 アペクシジェン アメリカ， インコーポレイテッド Ｃｄ－４０アゴニストを用いてがんを処置する方法
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
IL293613A (en) 2022-08-01
US20220411524A1 (en) 2022-12-29
JP2023505303A (ja) 2023-02-08
WO2021110930A1 (en) 2021-06-10
EP4069739A1 (en) 2022-10-12
CA3163777A1 (en) 2021-06-10
CN115052891A (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
US11730803B2 (en) Cancer immunotherapy using virus particles
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
Bleumer et al. Immunotherapy for renal cell carcinoma
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
US20220411524A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
CN111836647A (zh) Cd47阻断疗法和cd38抗体的组合
US20230270861A1 (en) Inhibitors of the Artemin Pathway for Treatment of Cancer
Wang et al. Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model
CN119326902A (zh) 癌症联合治疗的组合物与方法
EP3297668B1 (en) Combination of anti-fgfr4-antibody and bile acid sequestrant
JP2012506371A (ja) 樹状細胞を標的とするための組成物
JP2007515946A (ja) 抗腫瘍二元機能融合タンパク質の調製および適用
US20240009275A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
CN114225023B (zh) 抗csf-1r抗体联合抗pd-l1抗体的应用
WO2019133245A1 (en) Preventing cytokine release syndrome
US20240010740A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
EP4681707A1 (en) Method for treating diseases by using reparixin alone or in combination with anti-pd-1 antibody
EP4621058A1 (en) Immunoenhancing salmonella strain for treatment of cancer and use thereof
Sultana et al. Evolving Trends in Breast Cancer Immunotherapy: Recent Updates
AU2023356118A1 (en) Use of c/ebp-beta antagonist and immunomodulator
WO2020018364A1 (en) Anti-galectin-9 antibody and methods of use thereof